Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or "off-the-shelf," cell therapies for degenerative diseases and traumatic injury. Its competitive positioning rests on the AlloSCOPE platform, which aims to generate millions of consistent, low-cost doses from a single pluripotent stem cell line. Management has framed this as a decisive advantage over autologous therapies, which are typically produced one patient at a time at costs running into the hundreds of thousands of dollars per dose.
The flagship OpRegen program is partnered with Roche and Genentech, which provides both validation and non-dilutive capital while also concentrating clinical-timeline control in a partner's hands. Meanwhile, internally owned programs such as COR1 (corneal endothelial cell therapy), OPC1 (spinal cord injury), and the islet cell initiative (ILT1) represent a deliberate shift toward a broader, more self-owned pipeline that management calls "Lineage 3.0." This mix of partnered and internal assets is central to the company's medium-term market positioning.
The most consequential upcoming catalyst is further OpRegen data and partner-driven development decisions. Roche and Genentech's expansion of the GAlette Phase 2a study, combined with a recent $5 million milestone payment and the program's RMAT (Regenerative Medicine Advanced Therapy) designation, suggests the partners are preparing for potential later-stage trials. Any announcement of pivotal-study plans or additional milestone payments could materially shift investor sentiment.
Beyond OpRegen, investors will watch for initial safety and efficacy signals from the OPC1 DOSED study in chronic spinal cord injury, progress in the ReSonance hearing-loss collaboration with William Demant Invest, and updates on the Type 1 diabetes manufacturing scale-up, which recently passed an internal go/no-go milestone. On the analyst front, the consensus recommendation of roughly 2.0 (equivalent to "Outperform") reflects a broadly constructive but not uniformly bullish stance, with price targets ranging from $2.00 to $9.00 and an average near $4.25.
As a clinical-stage biotech, Lineage is less directly sensitive to interest rates and inflation than mature industrials, but it is not immune. Higher-for-longer rate environments tend to compress valuations of pre-revenue companies with distant cash flows, while risk-on or risk-off shifts in biotech capital flows can amplify volatility around binary events. Aging demographics and rising prevalence of age-related macular degeneration and diabetes provide durable, long-term demand tailwinds for its target indications.
Regulatory climate also matters. RMAT designation and the FDA's (U.S. Food and Drug Administration's) receptiveness to cell-based therapies can accelerate development timelines, while any tightening of reimbursement or safety standards could raise the bar for commercialization. Geopolitical factors carry a specific operational dimension here, as some Lineage employees and partners are based in Israel.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF (exchange-traded fund), or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. Investors tracking LCTX can use the Trend Prediction Engine alongside fundamental research to monitor shifts in the stock's technical posture as catalysts approach.
Looking toward 2026 and beyond, Lineage's trajectory will hinge on whether its partnered and internal programs convert scientific proof into commercial-grade manufacturing and regulatory milestones. The AlloSCOPE platform's ability to demonstrate consistent, low-cost production is a central long-term theme, because it underpins both margin sustainability and the economics of any future partnerships or commercialization deals.
Market expansion opportunities span ophthalmology, neurology, audiology, and diabetes, giving the company multiple shots on goal. However, cost-structure evolution remains a watch item, as rising research and development spending and partner-dependent revenue mean profitability is not imminent. Capital allocation priorities—balancing internal development against selective partnerships and equity raises—will shape dilution and sentiment. Competitive threats from other cell therapy and gene therapy developers, as well as regulatory decisions on regenerative medicine products, will also influence the long-term outlook. Consensus analyst expectations are constructive but wide-ranging, reflecting genuine uncertainty about execution timelines rather than a uniform view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XCNY | 31.86 | 0.04 | +0.14% |
| State Street SPDR S&P Emerging Markets ex-China ETF (XCNY) | |||
| LOTI | 26.99 | 0.03 | +0.13% |
| Liberty One Tactical Income ETF (LOTI) | |||
| RAFE | 51.28 | N/A | N/A |
| PIMCO RAFI ESG U.S. ETF (RAFE) | |||
| JMUB | 48.86 | -0.09 | -0.18% |
| JPMorgan Municipal ETF (JMUB) | |||
| GBND | 48.38 | -0.12 | -0.25% |
| Goldman Sachs Core Bond ETF (GBND) | |||
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with EDIT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | -7.64% | ||
| EDIT - LCTX | 44% Loosely correlated | +1.40% | ||
| MDGL - LCTX | 43% Loosely correlated | +0.51% | ||
| IMNM - LCTX | 41% Loosely correlated | +0.37% | ||
| FHTX - LCTX | 41% Loosely correlated | +0.98% | ||
| VIR - LCTX | 40% Loosely correlated | -17.82% | ||
More | ||||
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology
LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where LCTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 159 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 100 of 119 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for LCTX turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
LCTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.498). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.